EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines

The first approved COVID‐19 vaccines include Pfizer/BioNTech BNT162B2, Moderna mRNA‐1273 and AstraZeneca recombinant adenoviral ChAdOx1‐S. Soon after approval, severe allergic reactions to the mRNA‐based vaccines that resolved after treatment were reported. Regulatory agencies from the European Unio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Allergy
Main Authors: Sokolowska, Milena, Eiwegger, Thomas, Ollert, Markus, Torres, Maria J., Barber, Domingo, Del Giacco, Stefano, Jutel, Marek, Nadeau, Kari C., Palomares, Oscar, Rabin, Ronald L., Riggioni, Carmen, Vieths, Stefan, Agache, Ioana, Shamji, Mohamed H.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Eaaci Position Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8013422/
https://ncbi.nlm.nih.gov/pubmed/33452689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/all.14739
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados